Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705294 | 1.00 | HDAC8 (0.50) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL20363926 | 0.88 | HDAC8 (0.54) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL12780344 | 0.88 | HDAC8 (0.54) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL311225 | 0.85 | HDAC8 (0.49) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL20702565 | 0.82 | KDR (0.51) | HDAC8SLC6A3GRM4 | |
| SCHEMBL20702566 | 0.82 | KDR (0.51) | HDAC8SLC6A3GRM4 | |
| SCHEMBL5307700 | 0.81 | KCNQ3 (0.47) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL6955765 | 0.80 | CES2 (0.62) | TAS1R3TAS1R1TAS1R2CHRNA1CHRNG | |
| SCHEMBL22288575 | 0.80 | CHRNA1 (0.50) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 | |
| SCHEMBL22288577 | 0.80 | CHRNA1 (0.50) | HDAC8TAS1R3TAS1R1TAS1R2CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-11427553-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| WO-2020157188-A1 | DIHYDROOXADIAZINONES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157188-A1 | DIHYDROOXADIAZINONES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| EP-3661517-A1 | DIHYDROOXADIAZINONES | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| CN-111212647-A | Dihydroxadiazinones | 拜耳股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369633-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | HDAC8 2458/4885TAS1R3 4633/4885TAS1R1 4443/4885 |
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | HDAC8 2476/4885TAS1R3 4623/4885TAS1R1 4447/4885 |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | CCND2, DPYD, DHPS | HDAC8 2476/4885TAS1R3 4623/4885TAS1R1 4447/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | HDAC8 2458/4885TAS1R3 4633/4885TAS1R1 4443/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | HDAC8 2458/4885TAS1R3 4633/4885TAS1R1 4443/4885 |
| US-11427553-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | HDAC8 2458/4885TAS1R3 4633/4885TAS1R1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.